Harvard Bioscience (HBIO) Stock Overview
Develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
HBIO Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Harvard Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$2.82 |
| 52 Week Low | US$0.28 |
| Beta | 1.52 |
| 1 Month Change | -15.07% |
| 3 Month Change | -28.39% |
| 1 Year Change | -83.42% |
| 3 Year Change | -82.70% |
| 5 Year Change | -87.28% |
| Change since IPO | -96.21% |
Recent News & Updates
Recent updates
Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive But Perhaps Not Attractive Enough
Oct 20
Harvard Bioscience, Inc. (NASDAQ:HBIO) Just Reported, And Analysts Assigned A US$3.00 Price Target
Aug 14Does Harvard Bioscience (NASDAQ:HBIO) Have A Healthy Balance Sheet?
Jul 23Little Excitement Around Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Revenues As Shares Take 26% Pounding
May 29
Expanding SoHo, BTX, And Mesh MEA Will Open New Markets
Expansion of SoHo platform and BTX systems could drive revenue growth in industrial and academic markets through broader applications and bioproduction processes.Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?
May 02Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price Drop
Apr 11Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
Feb 07Why Investors Shouldn't Be Surprised By Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 31% Share Price Plunge
Feb 07Is Now An Opportune Moment To Examine Harvard Bioscience, Inc. (NASDAQ:HBIO)?
Nov 07Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Aug 07Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story
Jul 15Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01Shareholder Returns
| HBIO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -5.4% | 3.4% | 1.2% |
| 1Y | -83.4% | -9.2% | 16.3% |
Return vs Industry: HBIO underperformed the US Life Sciences industry which returned -9.2% over the past year.
Return vs Market: HBIO underperformed the US Market which returned 16.3% over the past year.
Price Volatility
| HBIO volatility | |
|---|---|
| HBIO Average Weekly Movement | 11.4% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HBIO's weekly volatility has decreased from 24% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 343 | John Duke | www.harvardbioscience.com |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems.
Harvard Bioscience, Inc. Fundamentals Summary
| HBIO fundamental statistics | |
|---|---|
| Market cap | US$17.72m |
| Earnings (TTM) | -US$57.41m |
| Revenue (TTM) | US$88.75m |
Is HBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBIO income statement (TTM) | |
|---|---|
| Revenue | US$88.75m |
| Cost of Revenue | US$38.21m |
| Gross Profit | US$50.54m |
| Other Expenses | US$107.94m |
| Earnings | -US$57.41m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.29 |
| Gross Margin | 56.94% |
| Net Profit Margin | -64.68% |
| Debt/Equity Ratio | 221.9% |
How did HBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/21 09:45 |
| End of Day Share Price | 2025/10/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Harvard Bioscience, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| Bruce Jackson | Benchmark Company |
| Paul Knight | Janney Montgomery Scott LLC |